Abstract: A crossflow filter includes a rigid cylindrical inner wall and a rigid cylindrical outer wall inner with an inelastic filter membrane positioned therebetween defining a retentate channel inside the filter membrane and a permeate channel outside the filter membrane. Further, the filter includes transition channels shaped and connected to the inner and outer walls to deliver a flow of fluid from an inlet port to the retentate channel and to capture flow flowing longitudinally along the cylindrical inner and outer walls from both the retentate and permeate channels to respective outlet ports.
Type:
Application
Filed:
May 8, 2020
Publication date:
August 27, 2020
Applicant:
Viatar LLC
Inventors:
Stephen S. KEANEY, Katherine J. SOOJIAN, Russell W. BOWDEN, Ilan K. REICH
Abstract: Filtering systems, methods, and devices, particularly adapted for apheresis of cellular bodies and more specifically for apheresis of circulating tumor cell bodies (CTCs) employs a cross-flow channel. Systems and methods as well as devices for such a system are described. Embodiments include a cylindrical filter that employs a thin micro-machined porous filter membrane with a regular array of pores and reliably pass blood while trapping CTCs.
Type:
Grant
Filed:
March 10, 2016
Date of Patent:
July 7, 2020
Assignee:
Viatar LLC
Inventors:
Stephen S. Keaney, Katherine J. Soojian, Russell W. Bowden, Ilan K. Reich
Abstract: Filtering systems, methods, and devices, particularly adapted for apheresis of cellular bodies and more specifically for apheresis of circulating tumor cell bodies (CTCs) employs a cross-flow channel. Systems and methods as well as devices for such a system are described. Embodiments include a cylindrical filter that employs a thin micro-machined porous filter membrane with a regular array of pores and reliably pass blood while trapping CTCs.
Type:
Application
Filed:
March 10, 2016
Publication date:
February 15, 2018
Applicant:
Viatar LLC
Inventors:
Stephen S. KEANEY, Katherine J. SOOJIAN, Russell W. BOWDEN, Ilan K. REICH
Abstract: A device can be used to retain circulating tumor cells (CTCs). The device can include a cross-flow module with a retentate channel and a permeate channel. A filter in the cross-flow module can separate the retentate channel from the permeate channel. The filter can be constructed such that CTCs are retained in the retentate channel while other cells can pass through the filter into the permeate channel. A recirculation channel can direct a flow from an outlet of the retentate channel back to an inlet of the retentate channel to thereby concentrate CTCs in the retentate flow.
Type:
Application
Filed:
December 28, 2016
Publication date:
June 22, 2017
Applicant:
Viatar LLC
Inventors:
Cornelis Johannes Maria van RIJN, Ilan K. REICH
Abstract: A device can be used to retain circulating tumor cells (CTCs). The device can include a cross-flow module with a retentate channel and a permeate channel. A filter in the cross-flow module can separate the retentate channel from the permeate channel. The filter can be constructed such that CTCs are retained in the retentate channel while other cells can pass through the filter into the permeate channel. A recirculation channel can direct a flow from an outlet of the retentate channel back to an inlet of the retentate channel to thereby concentrate CTCs in the retentate flow.
Type:
Grant
Filed:
August 6, 2014
Date of Patent:
January 17, 2017
Assignee:
VIATAR LLC
Inventors:
Cornelis Johannes Maria van Rijn, Ilan K. Reich
Abstract: Embodiments of the present disclosure are directed to the separation/capture of specific cells and/or contaminants, as well as the determination, monitoring, and treatment of cancer. Moreover, some embodiments are directed to methods, systems and devices for removing cancer, stem and/or tumor cells in vivo or in vitro from a bodily fluid to prevent or impede the proliferation of a cancer. Some embodiments provide a blood-compatible filter comprising, for example, a membrane provided with a number of openings (preferably precise) which yield minimal detrimental effect both quantitatively and qualitatively on cells present in the bodily fluid during the separation process. For example, in some embodiments, a majority percentage of circulating tumor cells are captured by a filter while a majority percentage of leukocytes, for example, are allowed to pass, where the passed leukocytes retain their vitality.
Type:
Application
Filed:
January 24, 2014
Publication date:
July 10, 2014
Applicant:
VIATAR LLC
Inventors:
Cornelis Johannes Maria van RIJN, Jacob BAGGERMAN, Ilan REICH
Abstract: Embodiments of the present disclosure are directed to the separation/capture of specific cells and/or contaminants, as well as the determination, monitoring, and treatment of cancer. Moreover, some embodiments are directed to methods, systems and devices for removing cancer, stem and/or tumor cells in vivo or in vitro from a bodily fluid to prevent or impede the proliferation of a cancer. Some embodiments provide a blood-compatible filter comprising, for example, a membrane provided with a number of openings (preferably precise) which yield minimal detrimental effect both quantitatively and qualitatively on cells present in the bodily fluid during the separation process. For example, in some embodiments, a majority percentage of circulating tumor cells are captured by a filter while a majority percentage of leukocytes, for example, are allowed to pass, where the passed leukocytes retain their vitality.
Type:
Application
Filed:
March 31, 2011
Publication date:
October 6, 2011
Applicant:
Viatar LLC
Inventors:
Cornelis Johannes Maria van Rijn, Jacob Baggerman, Ilan Reich